Singh, H. (2018). U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationSingh, H. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationSingh, H. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.